The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Shares of infrastructure construction company Primoris (NYSE:PRIM) jumped 7% in the afternoon session after the company was set to be added to the S&P SmallCap 600 index. This quarterly rebalancing, ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Amazon has started issuing payments to eligible Prime members as part of a $2.5 billion settlement over federal allegations that it misled customers. The online retailer agreed to the payouts in ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Prim is the newest venue from the creators of Ghost Baby. Several bottles are on display at the bar. Ross Van Pelt To continue reading this content, please enable ...

Is 170,141,183,460,469,231,731,687,303,715,884,105,727 prime? Before you ask the Internet for an answer, can you consider how you might answer that question without a ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...